Get the Stockscreener App
17.32
3.99%
-0.72
After Hours:
17.32
Arcturus Therapeutics Holdings Inc stock is traded at $17.32, with a volume of 644.22K.
It is down -3.99% in the last 24 hours and up +16.32% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
See More
Previous Close:
$18.04
Open:
$17.65
24h Volume:
644.22K
Relative Volume:
1.21
Market Cap:
$470.32M
Revenue:
$157.75M
Net Income/Loss:
$-29.73M
P/E Ratio:
-14.93
EPS:
-1.16
Net Cash Flow:
$-21.00M
1W Performance:
-2.97%
1M Performance:
+16.32%
6M Performance:
+21.50%
1Y Performance:
-13.01%
1-Day Range:
$16.54
$17.83
1-Week Range:
$16.54
$18.69
52-Week Range:
$8.04
$25.88
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
17.32 | 488.51M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-28-25 | Initiated | BTIG Research | Buy |
| Aug-12-24 | Initiated | Leerink Partners | Outperform |
| Dec-13-23 | Initiated | Canaccord Genuity | Buy |
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
What is HC Wainwright's Estimate for ARCT Q3 Earnings? - MarketBeat
Invesco Ltd. Acquires 15,836 Shares of Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Coverage Initiated by Analysts at HC Wainwright - MarketBeat
Will Arcturus Therapeutics Holdings Inc. benefit from rate cuts2025 Price Momentum & Capital Efficient Trade Techniques - beatles.ru
Vestal Point Capital LP Acquires New Position in Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat
Real time alert setup for Arcturus Therapeutics Holdings Inc. performanceWeekly Stock Analysis & Capital Efficiency Focused Ideas - Newser
Is Arcturus Therapeutics Holdings Inc. backed by strong institutional buyingJuly 2025 PreEarnings & Weekly Top Stock Performers List - خودرو بانک
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Rating of "Buy" by Analysts - MarketBeat
Applying sector rotation models to Arcturus Therapeutics Holdings Inc.Dollar Strength & Low Drawdown Momentum Ideas - Newser
Automated trading signals detected on Arcturus Therapeutics Holdings Inc. - Newser
What’s the beta of Arcturus Therapeutics Holdings Inc. stock2025 Volume Leaders & Weekly Watchlist of Top Performers - خودرو بانک
Is Arcturus Therapeutics Holdings Inc. stock undervalued right nowJuly 2025 Sector Moves & Verified Chart Pattern Trade Signals - خودرو بانک
Does Arcturus Therapeutics Holdings Inc. qualify in momentum factor screeningEarnings Recap Summary & Smart Money Movement Alerts - Newser
Arcturus Therapeutics Holdings Inc. recovery potential after sell offMarket Activity Recap & Precise Entry and Exit Recommendations - Newser
What Fibonacci levels say about Arcturus Therapeutics Holdings Inc. reboundEarnings Overview Report & Reliable Intraday Trade Plans - Newser
Live market analysis of Arcturus Therapeutics Holdings Inc.July 2025 EndofMonth & Free Growth Oriented Trading Recommendations - Newser
Multi factor analysis applied to Arcturus Therapeutics Holdings Inc.Dip Buying & Long-Term Growth Stock Strategies - Newser
Tools to monitor Arcturus Therapeutics Holdings Inc. recovery probabilityMarket Trend Review & High Conviction Buy Zone Picks - Newser
Relative strength of Arcturus Therapeutics Holdings Inc. in sector analysis2025 Support & Resistance & Weekly Momentum Picks - Newser
Can you recover from losses in Arcturus Therapeutics Holdings Inc.Gap Down & Daily Risk Controlled Trade Plans - Newser
Is Arcturus Therapeutics Holdings Inc. forming a reversal patternQuarterly Earnings Report & Free Fast Entry Momentum Trade Alerts - Newser
Vanguard Group Inc. Increases Stock Position in Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat
Is a relief rally coming for Arcturus Therapeutics Holdings Inc. holdersDividend Hike & Weekly Momentum Picks - Newser
Volume spikes in Arcturus Therapeutics Holdings Inc. stock – what they meanNew Guidance & Verified Trade Idea Suggestions - Newser
Visual trend scoring systems applied to Arcturus Therapeutics Holdings Inc.2025 Year in Review & Free Expert Verified Stock Movement Alerts - Newser
How institutional ownership impacts Arcturus Therapeutics Holdings Inc. stockRecession Risk & Low Risk Entry Point Tips - Newser
Is Arcturus Therapeutics Holdings Inc. vulnerable to short sellersEarnings Risk Summary & Stepwise Trade Signal Guides - خودرو بانک
Top chart patterns to watch in Arcturus Therapeutics Holdings Inc.July 2025 Update & Free Long-Term Investment Growth Plans - Newser
When is the best time to exit Arcturus Therapeutics Holdings Inc.Forecast Cut & AI Based Buy and Sell Signals - Newser
Signal strength of Arcturus Therapeutics Holdings Inc. stock in tech scannersJuly 2025 Spike Watch & Capital Protection Trading Alerts - Newser
How to integrate Arcturus Therapeutics Holdings Inc. into portfolio analysis toolsEarnings Recap Summary & Risk Managed Investment Entry Signals - Newser
How sentiment analysis helps forecast Arcturus Therapeutics Holdings Inc.Portfolio Update Report & Growth Oriented Trade Recommendations - Newser
Is Arcturus Therapeutics Holdings Inc. affected by consumer sentimentJuly 2025 Decliners & Accurate Entry and Exit Point Alerts - خودرو بانک
How to build a dashboard for Arcturus Therapeutics Holdings Inc. stockEarnings Miss & Long-Term Growth Stock Strategies - Newser
Can Arcturus Therapeutics Holdings Inc. Escape Recent Bear Channel2025 Momentum Check & Pattern Based Trade Signal System - beatles.ru
Intraday pattern recognizer results for Arcturus Therapeutics Holdings Inc.2025 Breakouts & Breakdowns & Safe Entry Zone Tips - Newser
Arcturus Therapeutics Holdings Inc. $ARCT Shares Purchased by AlphaQuest LLC - MarketBeat
How to track smart money flows in Arcturus Therapeutics Holdings Inc.2025 Technical Overview & Weekly Watchlist for Hot Stocks - Newser
Should You Buy Arcturus Therapeutics (ARCT) After Golden Cross? - sharewise.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2025 Earnings Call Transcript - MSN
US High Growth Tech Stocks To Watch Now - simplywall.st
Using data tools to time your Arcturus Therapeutics Holdings Inc. exit2025 Support & Resistance & Growth Focused Stock Pick Reports - Newser
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):